Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

The earnings call presents a mixed picture. While there are positive elements like growth in medical essentials and connected care, strong cash flow, and confidence in future revenue and margin performance, there are concerns. The decline in biopharma systems, adjusted gross margin decrease, and lack of clarity on certain future projections temper optimism. The strategic focus on share repurchases and productivity improvements is positive, but headwinds from Alaris and China, and the temporary ship hold on ChloraPrep, introduce uncertainties. Overall, the sentiment is balanced, leading to a neutral stock price prediction.
The strategic plan outlines positive initiatives such as share buybacks, innovation investments, and cost optimization, which are likely to bolster market sentiment. Despite challenges like tariff headwinds and revenue declines in specific segments, the company maintains stable margins and optimistic EPS growth. The Q&A insights reveal effective management of external factors and growth strategies, further supporting a positive outlook. These elements collectively suggest a positive stock price movement over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.